Image: Testmate Health

Testmate Health, a startup focused on sexual health diagnostics, has successfully raised $6 million in seed funding to revolutionize STI testing. The funding round, led by RH Capital with participation from The Helm, Amboy Street Ventures, Liechtsteiner Foundation, Zürcher Kantonal Bank and, marks a significant milestone for Testmate’s mission to improve access to essential diagnostics while ensuring accuracy and privacy.

Unlike traditional at-home STI tests that require mailing samples to a lab and waiting days for results, Testmate’s innovative urine-based test promises reliable results in under 30 minutes, right from the comfort of home. With an estimated 85% of STIs being asymptomatic, Testmate’s rapid testing solution addresses the challenge of undiagnosed infections, which can lead to severe health complications if left untreated.

Siew-Veena Sahi, Founder of Testmate Health, and the remaining leadership team have combined experience in clinical development, regulatory strategy, and commercialization of at-home diagnostics tests. This seed round will enable Testmate to speed up product development, testing, and market validation.

Sahi shares: “Our goal is making a positive impact on global public health by helping end the silent epidemic of sexually transmitted infections for chlamydia and gonorrhea. Through Testmate’s low-cost urine-based DNA platform detection technology, we’re empowering individuals to take control of their sexual health with accessible, accurate, and convenient testing solutions, from home.”

Show CommentsClose Comments

Leave a comment